FDA issues CRL to Aldeyra’s reproxalap drug application

Aldeyra Therapeutics will not pursue new trials and will request a Type A meeting with the FDA. Credit: Sai Thaw Kyar / Shutterstock.com.



  • Aldeyra FDA CRL